SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Issues journals

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P. 37–41

O.D. Bragina1, A.G.Vorobyeva5, V.M. Tolmachev5, A.M. Orlova5, V.I. Chernov1,2, S.M. Deyev2,4, G.N. Proshkina4, A.A. Shulga4, M.S. Larkina3, A.A. Medvedeva1, R.V. Zelchan1

In vitro and in vivo Evaluation of the Radiochemical Compound Based on
99mTechnetium Labelled DARPin9_29 for Molecular Visualization
of Malignancies Overexpressing Her2/neu

1. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, Tomsk, Russia.
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
2. National Research Tomsk Polytechnic University, Tomsk, Russia
3. Siberian State Medical University, Tomsk, Russia
4. Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
5. Uppsala University, Uppsala, Sweden

Abstract

Purpose: Evaluation of a radiopharmaceutical based on 99mTc-labeled targeted molecules DARPin9_29 for radionuclide diagnostics of malignancies with Her2/neu overexpression.

Material and methods: The DARPin9_29 sequence was amplified from the plasmid pET-DARP-6HIS for the DARPin9_29-His6 gene expression in E. coli cells. The eluent of 99mTcO4– (400–500 μl, 4 GBq) was added to the kit and incubated at a temperature of 100 °C for 20 minutes. After incubation, 40 μl of tricarbonyl technetium was added to 168 μg of DARPin9_29 in 100 μl of PBS (sodium phosphate buffer), followed by incubation at 40 °C for 60 minutes. The radiochemical yield and purity were determined by thin layer radiochromatography, the purification was performed using NAP-5 cleansing columns (GE Healthcare). Cell lines with different levels of Her2/neu expression were used: SKOV-3> BT474 >> DU-145 for the determination of the radiopharmaceutical specificity. Her2/neu expressing cell line SKOV-3 was used for in vitro study. The study was conducted 6 hours after the administration of the drug.

Results: The radiochemical yield was 72 ± 8 %, the radiochemical purity after purification was 98.7 ± 1.0 %. The stability in PBS (phosphate buffered saline) solution after 1 hour was 99.8 ± 0.2; after 3 hours – 98.2 ± 0.1. In vitro studies showed that the accumulation of explored compound was directly proportional to the level of Her2/neu expression in cells, while blocking the receptors with an excess of unlabeled protein showed a significant reduction in binding in the group of cells. Data on biodistribution and SPECT/CT in the body of the animal BALB/c nu/nu demonstrated rapid removal of the compound from the blood stream and high accumulation in the liver, kidney and bladder 6 hours after the introduction of the radiopharmaceutical.

Conclusion: The studies demonstrated high radiochemical yields and purity, as well as stability of the studied compound. The results of in vitro and in vivo analysis showed the specificity and affinity of the radiopharmaceutical to the Her2/neu receptor on the surface of tumor cells. The high accumulation of the drug in the liver and kidneys, detected in in vivo studies, is probably due to the lipophilicity of the 99mTc(CO)3-histidine tag and indicates the limitation of its further clinical use in assessing the condition of the above organs, which will require additional diagnostic methods, as well as possible modification chemical structure.

Key words: malignancies, Her2/neu, radionuclide diagnostics, DARPin9_29

Для цитирования: Bragina OD, Vorobyeva AG, Tolmachev VM, Orlova AM, Chernov VI, Deyev SM, Proshkina GN, Shulga AA, Larkina MS, Medvedeva AA, Zelchan RV. In vitro and in vivo Evaluation of the Radiochemical Compound Based on 99mTechnetium Labelled DARPin9_29 for Molecular Visualization of Malignancies Overexpressing Her2/neu. Medical Radiology and Radiation Safety. 2020;65(1):37-41. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-1-37-41

Список литературы / References

  1. Чернов ВИ, Медведева АА, Синилкин ИГ, и др. Ядерная медицина в диагностике и адресной терапии злокачественных новообразований. Бюллетень сибирской медицины. 2018;17(1):220-31. [Chernov VI, Medvedeva AA, Sinilkin IG, Zelchan RV, Bragina OD, Choynzonov EL. Nuclear medicine as a tool for diagnosis and targeted cancer therapy. Bulletin of Siberian Medicine. 2018;17(1):220-31. (In Russ.)].
  2. Чернов ВИ, Брагина ОД, Синилкин ИГ, и др. Радиоиммунотерапия: современное состояние проблемы. Вопросы онкологии. 2016;62(1):24-30. [Chernov VI, Bragina OD, Sinilkin IG, Medvedeva AA, Zel’chan RV Radioimmunotherapy: current state of the problem. Oncology Issues. 2016;62(1):24-30. (In Russ.)].
  3. Брагина ОД, Чернов ВИ, Зельчан РВ, и др. Альтернативные каркасные белки в радионуклидной диагностике злокачественных заболеваний. Бюллетень сибирской медицины. 2019;3(18):125-33. [Bragina OD, Chernov VI, Zelchan RV, Sinilkin IG, Medvedeva AA, Larkina MS. Alternative scaffolds in radionuclide diagnosis of malignancies. Bulletin of Siberian Medicine. 2019;18(3):125-33. (In Russ.)].
  4. Чернов ВИ, Брагина ОД, Синилкин ИГ, и др. Радиоиммунотерапия в лечении злокачественных образований. Сибирский онкологический журнал. 2016;15(2):101-6. [Chernov VI, Bragina OD, Sinilkin IG, Medvedeva AA, Zel’chan RV Radioimmunotherapy in the treatment of malignancies. Siberian journal of oncology. 2016;15(2):101-6. (In Russ.)].
  5. Tamaskovic R, Simon M, Stefan N, Schwill M, Plückthun A. Designed ankyrin repeat proteins (DARPins) from research to therapy. Methods Enzymol. 2012;503:101–34.
  6. Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol. 2011;22:849-57.
  7. Брагина ОД, Ларькина МС, Стасюк ЕС, и др. Разработка высокоспецифичного радиохимического соединения на основе меченных 99mТс рекомбинантных адресных молекул для визуализации клеток с гиперэкспрессией Her-2/ neu. Бюллетень сибирской медицины. 2017;16(3):25-33. [Bragina OD, Larkina MS, Stasyuk ES, Chernov VI, Yusubov MS, Skuridin VS et al. Development of highly specific radiochemical compounds based on 99mTc-labeled recombinant molecules for targeted imaging of cells overexpressing Her-2/ neu. Bulletin of Siberian Medicine. 2017;16(3):25-33. (In Russ.)].
  8. Vorobyeva A, Bragina O, Altai M, Mitran B, Orlova A, Shulga A et al. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. Contrast Media & Molecular Imaging. 2018; 2018: 6930425.
  9. Goldstein R, Sosabowski J, Livanos M, Leyton J, Vigor K, Bhavsar G et al. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. Eur J Nucl Med Mol Imaging. 2015;42(2):288-301.
  10. Lindbo S, Garousi J, Mitran B, Altai M, Buijs J, Orlova A et al. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. J Nucl Med. 2018;59(1):93-9.
  11. Plückthun A Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015; 55:489-511.
  12. Garousi J, Honarvar H, Andersson KG, Mitran B, Orlova A, Buijs J et al. Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in vivo Expression of Carbonic Anhydrase IX. Mol Pharm. 2016 Nov 7;13(11):3676-87.
  13. Nicholes N, Date A, Beaujean P, Hauk P, Kanwar M, Ostermeier M. Modular protein switches derived from antibody mimetic proteins. Protein Engineering, Design and Selection. 2016; 29:77-85.
  14. Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O et al. Non-invasive in vivo imaging of tumour- associated cathepsin B by a highly selective inhibitory DARPin. Theranostics. 2017; 8:2806-21.
  15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse a survival with amplification of the Her-2/neu oncogenes. Science. 1987; 235:177–82.
  16. Zavyalova M, Vtorushin S, Krakhmal N, Savelieva O, Tashireva L, Kaigorodova E et al. Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes. Experimental Oncology. 2016;38(2):122-27.
  17. Vorobyeva A, Garousi J, Tolmachev V, Schulga A, Konovalova E, Deyev SM et al. Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPinG3. Scientific Reports. 2019; 9 (1): 9405.
  18. Чернов ВИ, Брагина ОД, Синилкин ИГ и др. Радионуклидная тераностика злокачественных образова- ний. Вестник рентгенологии и радиологии. 2016;97(5):306-13. [Chernov VI, Bragina OD, Sinilkin IG, Medvedeva AA, Zel’chan RV Radionuclide teranostic of malignancies. Journal of Radiology and Nuclear Medicine. 2016;97(5):306-13. (In Russ.)].

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The research is carried out within the framework of the Federal target program «Development of the pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond» on the topic «Preclinical research of a radiopharmaceutical drug based on 99mTc-labeled recombinant targeted molecules for radionuclide diagnostics of cancer diseases with hyperexpression of Her-2/neu».

Contribution. Article was prepared with equal participation of the authors.

Article received: 28.05 2018. Accepted for publication: 11.12.2019.


Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P.42–47

V.M. Sotnikov, G.A. Panshin, V.A. Solodkiy, V.D. Chkhikvadze, V.P. Kharchenko, N.V. Nudnov, S.D. Trotsenko, V.N. Vasilev, A.Yu. Smyslov, A.A. Morgunov

The Overall Survival of Non-Small Cell Lung Cancer Patients Group pN2
after Radical Surgery and Postoperative Radiotherapy

Russian Scientific Center of Roentgenoradiology, Moscow, Russia
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: Comparative analysis of the overall survival (OS) in different subgroups of the patients with non-small cell lung cancer (NSCLC) with affected mediastinal lymph nodes (pN2) after surgical and combined treatment using postoperative radiotherapy (PORT).

Material and methods: A comparative assessment of the overall survival of 243 patients with NSCLC stages IIIA, IIIB (рT1–4N2M0) was carried out: the I group – 79 patients after radical (R0) surgical treatment (lobe/bilobectomy, pulmonectomy with ipsilateral mediastinal lymph node dissection) and the second group – 164 patients after the combined modality therapy with the same volume of surgery and postoperative radiotherapy in the mode of hypofractionation (daily dose 3 Gy, 5 times a week, TD = 36–39 Gy (EQD2 = 43.2–46.8 Gy, α/β = 3) or classical fractionation (2 Gy, 5 times a week, TD = 44 Gy). We analyzed subgroups of men and women, patients younger than 60 years and older, with central and peripheral cancer, squamous cell carcinoma and adenocarcinoma, with different gradation of tumors according to the criterion T (pT1–4).

Results: In the compared groups, 2-year and 5-year OS was significantly higher in the PORT group (62.4 and 31.6 vs 44.8 % and 12.3 %, p = 0.0028), at the expense of male patients (62.4 and 31.6 % vs 44.8 and 12.3 %, p = 0.0028), patients with central cancer (59.2 and 43.7 % vs 36.3 % and n/a, p = 0.0023), patients with squamous cell carcinoma (64.0 % and 43.1 % vs 42.3 % and 6.7 %, p = 0.0006), patients older than 60 years (74.8 and 46.2 % vs 45.1 % and n/a, p = 0.007). A more detailed analysis revealed that PORT significantly increased 2- and 5-year OS in the central squamous cell carcinoma of the lung (67.3 and 53.0 % vs. 33.3 and 0 %, respectively, p = 0.0013), and in pT3–4 tumors (2-year OS 57.1 vs. 36.4 %, respectively, p = 0.0102). There was only a tendency of increasing OS after the PORT in T2 tumors (5-year OS 31.1 vs 15.4 %, respectively, p = 0.1319). In T1 tumors, no differences in OS were found, possibly due to the small number of cases (27). In peripheral squamous cell carcinoma there was a statistically insignificant increasing of 5-year OS – 7 %. There was no significant differences in OS survival were obtained in central and peripheral lung adenocarcinoma between the I and II groups.

Conclusion: In the patients with non-small cell lung cancer pN2, radically operated (R0) in the volume of lobe/bilobectomy, pulmonectomy with ipsilateral mediastinal lymph node dissection, PORT can be recommended for central squamous cell carcinoma pT1–4. In the patients with peripheral squamous cell carcinoma, PORT can be discussed for the patients with individually assessed high risk of the locoregional relapse. PORT, within the scope of irradiation and total doses used in this study, has no age restrictions. The feasibility of PORT for radically operated patients with pN2 lung adenocarcinoma requires further study.

Key words: non-small cell lung cancer, surgical treatment, postoperative radiation therapy, overall survival

For citation: Sotnikov VM, Panshin GA, Solodkiy VA, Chkhikvadze VD, Kharchenko VP, Nudnov NV, Trotsenko SD, Vasilev VN, Smyslov AYu, Morgunov AA. The Overall Survival of Non-Small Cell Lung Cancer Patients Group pN2 after Radical Surgery and Postoperative Radiotherapy. Medical Radiology and Radiation Safety. 2020;65(1):42-47. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-1-42-47

Список литературы / References

  1. Feng W, Zhang Q, Fu X-L, et al. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015;15:348-57. DOI: 10.1186/s12885-015-1326-6.
  2. Robinson CG, Patel AP, Bradley JD, et al. Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. J Clin Oncol. 2015;33(8):870-6.
  3. Троценко СД, Солодкий ВА, Сотников ВМ, и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость. Вопросы онкологии. 2015(1):71-6. [Trotsenko SD, Solodky VA, Sotnikov VM et al. The results of surgical and combined treatment for non-small cell lung cancer with postoperative radiotherapy in the mode of hypofractioning. Overall and disease-specific survival. Problems in Oncology. 2015(1):71-6. (In Russ.)].
  4. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 (Suppl. 4): iv1–iv21.
  5. Bezjak A, Temin S, Franklin G, et al. Definitive and Adjuvant Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol. 2015;33(18):2100-5. DOI: 10.1200/JCO.2014.59.2360.
  6. Billiet C, Dirix P, Meijnders P, Ruysscher DD, et al. Prognostic Models for Patient Selection in Postoperative Radiotherapy: Ready for Use? J Thorac Oncol. 2018;13(12):1809-11.
  7. Gomez JA, Gonzalez F, Counago et al. Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society. Clin Transl Oncol. 2016;18:331-41. DOI: 10.1007/s12094-015-1374-z.
  8. Mikell JL, Gillespie TW, Hall WA, et al. Post-operative radiotherapy (PORT) is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes. J Thorac Oncol. 2015;10(3):462-71.
  9. Hui Z, Dai H, Liang J, et al. Selection of Proper Candidates with Resected IIIA-N2 Non-small Cell Lung Cancer for Postoperative Radiotherapy: A New Prediction Model. Int J Radiat Oncol Biol Phys. 2008;72(1). Suppl. A.1015.
  10. Cox JD, Scott CB, Byhardt RW, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999;43(3):505-9.
  11. Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol. 2014;5(5):1048-54.

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 21.05.2019. Accepted for publication: 11.12.2019.


Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P. 54–58

T. Medjadj1, A.I. Ksenofontov1, A.V. Dalechina2

An Effective Method of Simulation for the Leksell Gamma Knife Perfexion by Rotating Particles in the Phase Space File

1. National Research Nuclear University (Moscow Engineering Physics Institute) MEPhI, Moscow, Russia;
2. OJSC Neurosurgery Business Center, Moscow GammaKnife Center, Moscow, Russia
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Реферат

Purpose: To develop an effective method of Monte Carlo simulation of the GammaKnife Perfexion system by rotating particles in the phase space file (PSF). This method does not require simulating of all 192 sources that are distributed in the conical form of the Perfexion collimator. The simulation was performed only for 5 out of 192 sources for each collimator size.

Material and methods: Monte Carlo simulation of dose distribution for previous models of GammaKnife system requires phase space file for only one source, since this phase space is identical for all the 201 sources. The Perfexion model is more complex due to the non-coaxial positions of the sources and the complexity of the collimator system itself.
In this work, we present an effective method to simulate the Perfexion model using a phase space file. Penelope Monte Carlo code was used to perform this simulation. In this method, the PSF was obtained for one source in each ring, resulting in five files for each collimator size. PSF for other sources were created by azimuthal redistribution of particles, in the obtained PSF, by rotation around the Z-axis. The phase space files of the same ring were then stored together in a single file.

Results: The paper presented MC simulation using the azimuthal redistribution of particles in the phase space file by rotation around the Z-axis. The simulation has been validated comparing the dose profiles and output factors with the data of the algorithm TMR10 planning system Leksell Gamma Plan (LGP) in a homogeneous environment. The acceptance criterion between TMR10 and Monte Carlo calculations for the profiles was based on the gamma index (GI). Index values more than one were not detected in all cases, which indicates a good agreement of results. The differences between the output factors obtained in this work and the TMR10 data for collimators 8 mm and 4 mm are 0.74 and 0.73 %, respectively.

Conclusion: In this work successfully implemented an effective method of simulating the Leksell Gamma knife Perfexion system. The presented method does not require modeling for all 192 sources distributed in the conical form of the Perfexion collimator. The simulation was performed for only five sources for each collimator and their files PSF were obtained. These files were used to create the PSF files for other sources by azimuthal redistribution of particles, in these files, by rotation around the Z-axis providing correct calculations of dose distributions in a homogeneous medium for 16, 8 and 4 mm collimators.

Ключевые слова: Gamma-Knife Perfexion, Monte Carlo simulation, file phase field

Для цитирования: Medjadj T, Ksenofontov AI, Dalechina AV. An Effective Method of Simulation for the Leksell Gamma Knife Perfexion by Rotating Particles in the Phase Space File. Medical Radiology and Radiation Safety. 2020;65(1):54-8. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-1-54-58

Список литературы / References

  1. Maitz A, Flickinger J, Lunsford L. Gamma Knife Technology and Physics: Past, Present, and Future. Lunsford LD, Kondziolka D, Flickinger JC (eds): Gamma Knife Brain Surgery. Prog Neurol Surg. Basel, Karger. 1998;14:5-20.
  2. Голанова АВ, Костюченко ВВ. Нейрорадиохирургия на Гамма-Ноже. В сб.: История стереотаксиса и радиохирургии. ред. Костюченко ВВ. – Москва, 2018;121-31. [Golanov AV, Kostjuchenko BB. Neuroradiosurgery with Gamma Knife. In: History of Stereoraxy and Radiosurgery. Kostjuchenko BB, ed. Moscow. 2018:121-31. (In Russ.)].
  3. Yuan J, Lo SS, Zheng Y, Sohn JW, Sloan AE, Ellis R, et al. Development of A Monte Carlo Model for Treatment Planning Dose Verification of the Leksell Gamma Knife Perfexion Radiosurgery System. J Applied Clinical Medical Physics. 2016;17(4):190–201.
  4. Lindquist C, Paddick I. The Leksell Gamma Knife Perfexion and Comparisons with Its Predecessors. Neurosurgery. 2007;61:130-40.
  5. Ma L, Kjäll P, Novotny J, Nordström H, Johansson J, Verhey L. A Simple and Effective Method for Validation and Measurement of Collimator Output Factors for Leksell Gamma Knife Perfexion. Phys Med Biol. 2009;54:3897-907.
  6. Salvat F, Jose M, Josep S. PENELOPE-2008: A Code System for Monte Carlo Simulation of Electron and Photon Transport, OECD-NEA, Report 6416, Issy-les-Moulineaux, France. 2009.
  7. Bush K, Zavgorodni SF, Beckham WA. Azimuthal Particle Redistribution for the Reduction of Latent Phase-Space Variance in Monte Carlo Simulations. Phys Med. Biol. 2007;52:4345-60.
  8. Brualla L, Sauerwein W. On the Efficiency of Azimuthal and Rotational Splitting for Monte Carlo Simulation of Clinical Linear Accelerators. Radiation Phys and Chemistry. 2010;79:929-32.
  9. Cho YB,  van Prooijen M, Jaffray DA, Islam MK. Verification of Source and Collimator Configuration for Gamma Knife Perfexion Using Panoramic Imaging. Med Phys. 2010;37(3):1325-31.
  10. Low DA, Harms WB, Mutic S, Purdy JA. A Technique for the Quantitative Evaluation of Dose Distributions. Med Phys. 1998;25:656-61.

PDF (RUS) Полная версия статьи

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 08.04.2019. Accepted for publication: 11.12.2019.

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P.48–53

N.S. Vorotyntseva, V.V. Orlova

Radiation Monitoring of the State of the Internal Organs in Newborns with General Therapeutic Hypothermia

Kursk State Medical University, Kursk, Russia.
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: Learning the state of the internal organs in newborns with severe perinatal asphyxia after general therapeutic hypothermia.

Material and methods: 80 newborns with severe perinatal asphyxia born from January 2014 to May 2019 in Kursk were under observation. In the first 6 hours of life, 52 patients were started with general therapeutic hypothermia (1st observation group), 28 newborns did not perform hypothermia (2nd control group). All children underwent a dynamic complex radiological examination, included ultrasound of the brain, abdominal organs and retroperitoneal space, echocardiography with Doppler, chest X-rays.

Results and discussion: In both groups of observations, radiation symptoms of liver and gallbladder changes were identified: a uniform increase in the echogenicity of the hepatic parenchyma (98.1 % of cases in group 1 and 100 % of cases in group 2, p > 0.05), visual “impoverishment” of the vascular pattern (98.1 % and 100 %, p > 0.05), hepatomegaly (19.2 % and 21.4 %, p > 0.05), thickening of the gallbladder walls, loose sediment or suspension in its lumen (7.7 % and 10.7 %, p > 0.05). All 80 examined patients showed a bilateral increase in echogenicity of the renal parenchyma with visual impoverishment of intraorgan blood flow and impaired corticomedullary differentiation. The described internal organs changes were reversible and due, in our opinion, mainly to the effect of asphyxiation and resuscitation measures.

According to the results of chest X-ray, we did not reveal the effect of therapeutic hypothermia on the incidence of hospital pneumonia: it was found in 34.6 % newborns from the 1st group and in 42.9 % – from the 2nd one (p > 0.05). However, in the first 14 days of life the respiratory failure caused by edematous and hemorrhagic changes in patient’s lungs was detected more often in patients from observation group then in patients from control group: respectively 76.9 % and 42.8 % of cases (p <0.05). This indicates a negative effect of general therapeutic hypothermia on the respiratory system of newborns with severe perinatal asphyxia.

Key words: newborns, severe perinatal asphyxia, general therapeutic hypothermia, radiation examination

For citation: Vorotyntseva NS, Orlova VV. Radiation Monitoring of the State of the Internal Organs in Newborns with General Therapeutic Hypothermia. Medical Radiology and Radiation Safety. 2020;65(1):48-53. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-1-48-53

Список литературы / References

  1. Буров АА, Горев ВВ, Горелик КД, и др. Терапевтическая гипотермия у новорожденных детей. Клинические рекомендации. Февраль 2019 г. [Электронный ресурс]. Режим доступа: http://neonatal22.ru/Protocol/protokol_hypothermia_2019.pdf (дата обращения:01.07.2019 г.) [Burov AA, Gorev VV, Gorelik KD, et al. Therapeutic hypothermia in newborns [Electronic resource]. Access mode: http://neonatal22.ru/Protocol/protokol_hypothermia_2019.pdf (access date: 01.07.2019). (In Russ.)].
  2. Зарубин АА, Михеева НИ, Филиппов ЕС, и др. Гипоксически-ишемическая энцефалопатия у новорожденных, рожденных в тяжелой асфиксии. Бюллетень ВСНЦ СО РАМН. 2017;2(2):95-101 [Zarubin AA, Miheeva NI, Filippov ES. et al. Hypoxic-ischemic encephalopathy in newborns born to severe asphyxia. Newsletter VSNC SO RAMN. 2017;2(2):95-101. (In Russ.)].
  3. Hayakawa, M, Ito Y, Saito S. Incidence and prediction of outcome in hypoxic-ischemic encephalopathy in Japan. Pediatr Int. 2014;56(2):215-21.
  4. Shah P, Riphagen S, Beyene J, Perlman M. Multiorgan dysfunction in infants with post-asphyxial hypoxic-ishaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2004;89:152-5.
  5. Задворнов АА, Голомидов ЕВ, Григорьев АВ. Неонатальная терапевтическая гипотермия: как она работает? Неонатология: новости, мнения, обучение. 2016;1:49-54.[Zadvornov AA, Golomidov EV, Grigor’ev AV. Neonatal therapeutic hypothermia:how to work? Neonatology: News, Opinions, Discussion. 2016;1:49-54. (In Russ.)].
  6. Edwards AD, Brocklehurst P, Gunn AJ, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischemic encephalopathy:synthesis and meta-analysis of trial data. BMJ. 2010;9:340-63.
  7. Григорьев ЕВ, Шукевич ДЛ, Плотников ГП, Тихонов НС. Терапевтическая гипотермия: возможности и перспективы. Клиническая медицина. 2014;9:9-16 [Grigor’ev EV, Shukevich DL, Plotnikov GP, Tihonov NS. Therapeutic hypothermia: opportunities and prospects. Clinical Medicine. 2014;9:9-16. (In Russ.)].
  8. Ионов ОВ. Протокол проведения лечебной гипотермии детей, родившихся в асфиксии. Неонатология. 2014;2:43-5. [Ionov OV. The protocol for therapeutic hypothermia of children born asphyxiated. Neonatology. 2014;2:43-5. (In Russ.)].
  9. UK TOBY Cooling Register Clinician’s Handbook. Version 4, May 2010 [Electronic resource]. – Mode of access: https://www.npeu.ox.ac.uk/downloads/files/tobyregister/Register-Clinicans-Handbook1-v4-07-06-10. Pdf. (access date: 15.06.2019).
  10. Шахматов ИИ, Вдовина ВМ, Бондарчука ЮА, и др. Гипоксическая гипоксия как фактор, активирующий систему гемостаза. Бюллетень сибирской медицины. 2007;1:67-72. [Shahmatov II, Vdovina VM, Bondarchuka YuA, et al. Hypoxic hypoxia as a factor activating the hemostatic system. Newsletter of Siberical Medicine. 2007;1:67-72. (In Russ.)].
  11. Володин НН. Неонатология. Национальное руководство. М.: ГЭОТАР-Медиа, 2008; 749 с. [Volodin NN. Neonatology. National Handbook. Moscow. 2008. 749 p. (In Russ.)].
  12. Хамчиев КМ. Легочное кровообращение и морфофункциональные изменения в легких крыс при сочетанном влиянии гипотермии и иммобилизации. Международный журнал экспериментального образования. 2015;7:153-4. [Hamchiev KM. Pulmonary circulation and morphofunctional changes in the lungs of rats with the combined effect of hypothermia and immobilization. International Journal of Eexperimental Education. 2015;7:153-4. (In Russ.)].
  13. Воротынцева НС, Орлова ВВ. Лучевое обследование новорожденных при общей терапевтической гипотермии. Медицинская радиология и радиационная безопасность. 2019;64(1):31-7. [Vorotynceva NS, Orlova VV. Radiation examination of newborns with general therapeutic hypothermia. Medical Radiology and Radiation Safety. 2019;64(1):31-7. (In Russ.)].
  14. Сиротина ЗВ. Внутриутробная пневмония. Клиническая лекция. Здравоохранение Дальнего Востока. 2015;3:75-80. [Sirotina ZV. Intrauterine pneumonia. Clinical lecture. Healthcare of the Far East. 2015;3:75-80. (In Russ.)].
  15. Дворяковский ИВ, Яцык ГВ. Ультразвуковая диагностика в неонатологии. М.: Атмосфера, 2012. 168 c. [Dvorjakovskij IV, Jacyk GV. Ultrasound diagnostics in neonatology. Moscow. 2012. 168 p. (In Russ.)].

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Informed consent. Parents of patients signed an informed consent for their children to participate in the study.

Article received: 16.08.2019. Accepted for publication: 11.12.2020.




Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P.59–64

A.K. Sukhoruchkin

Application of the ICRP Database for Calculation of the Dose Coefficient for Aerosol Having Multimodal Particle Size Distribution

National Research Centre “Kurchatov Institute”.
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: Development of a method for calculating radioactive aerosol dose coefficient when the aerosol particle size measurements resulted in a multimodal radionuclide activity distribution by particle diameters.

Material and methods: The physical prerequisite for the proposed method is that the multimodal distribution may be caused by the presence of several sources of aerosols with different particle sizes. In the ICRP database to each value of the aerosol dose coefficient there corresponds one of ten functions of log-normal (unimodal) distribution with specified parameters. In the developed method the result of the aerosol particle size measurement is approximated by the sum of said standard functions with weight factors of each of the functions defined such that the best least squares approximation is obtained. Then the dose coefficient of the aerosol under study is calculated based on the dose value additivity property, i.e. each weight factor is multiplied by a respective value of the dose coefficient from the ICRP database, and the obtained products are added up.

Results: There was carried out a series of numerical experiments, in each of which “experimental” points were simply plotted on a graph of a certain cumulative distribution function. Coordinates of the points are used as input for the programme implementing the developed algorithm. The calculated dose coefficient value is compared with the true value and/or the value obtained with the linear interpolation method using the AMAD.

Conclusion: Physical prerequisites and results of numerical experiments confirm the validity of the developed method.

Key words: radioactive aerosol, aerodynamic diameter of a particle, activity distribution, approximation, dose coefficient, ICRP database

For citation: Sukhoruchkin AK. Application of the ICRP Database for Calculation of the Dose Coefficient for Aerosol Having Multimodal Particle Size Distribution. Medical Radiology and Radiation Safety. 2020;65(1):59-64. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-1-59-64

Список литературы / References

  1. Международные основные нормы безопасности для защиты от ионизирующих излучений и безопасного обращения с источниками излучения. Серия изданий по безопасности № 115. – Вена: МАГАТЭ. 1997. 382 с. [IAEA. International Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources. Safety Series No. 115, 1996. (In Russ.)].
  2. Нормы радиационной безопасности (НРБ-99/2009). СП 2.6.1.2523-09. М. 2009. 100 с. [Radiation Safety Standards (NRB-99/2009). SP 2.6.1.2523-09. Moscow. 2009, 100 p. (In Russ.)].
  3. The ICRP Database of Dose Coefficients: Workers and Members of the Public. ICRP CD-ROMS (Version 3.0, 1998–2011).
  4. Human Respiratory Tract Model for Radiological Protection, ICRP Publication 66, Annals of ICRP, 1994.
  5. Райст П. Аэрозоли. Введение в теорию. М.: «МИР». 1987. 287 с. [Reist PC. Introduction to Aerosol Science. New York: Macmillan, 1984, 299 p. (In Russ.)].
  6. Сухоручкин АК. Расчет дозового коэффициента аэрозоля произвольной дисперсности. В сб.: «Проблемы безопасности атомных электростанций и Чернобыля». 2005. Вып. 3, ч. 1. С. 98–101. [Sukhoruchkin AK. Calculation of the dose factor for aerosol having arbitrary particle size distribution. In: Safety issues related to nuclear power plants and Chernobyl. 2005. Issue 3, Part 1, P. 98–101. (In Russ.)].
  7. Maple 2018.2. Licensed to: NRC Kurchatov Institute. www.maplesoft.com.
  8. Фукс НА. Механика аэрозолей. М.: Изд-во АН СССР. 1955. 352 с. [Fuks NA. The Mechanics of Aerosols. Moscow, USSR Academy of Sciences Publishing House. 1955. 352 p. (In Russ.)].

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The author declares no conflict of interest.

Acknowledgments. The author expresses sincere gratitude to Shinkarev CM, Dr Sci Tech, for comments and discussion of this article.

Financing. This work was supported by the Research Center “Kurchatov Institute” (order of August 14, 2019, No. 1808).

Article received: 23.01.2020. Accepted for publication: 27.01.2020.

  1. 65-71_Balkanov_Stepanova_eng
  2. 72-78_Shandala_et_al_eng
  3. 79_Anniversary_of_Velikhov_eng
  4. 80-81_Commemoration_of_Lindenbraten_eng

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2770892
Today
Yesterday
This week
Last week
This month
Last month
For all time
3219
2948
25438
25438
78635
75709
2770892
Forecast today
3312

Your IP:216.73.216.21
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх